{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:52:55Z","timestamp":1777351975083,"version":"3.51.4"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["K23MH130728"],"award-info":[{"award-number":["K23MH130728"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR002367"],"award-info":[{"award-number":["KL2TR002367"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["P30HD106451"],"award-info":[{"award-number":["P30HD106451"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40272-025-00683-9","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:20:20Z","timestamp":1738581620000},"page":"307-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neuroimaging as a Tool for Advancing Pediatric Psychopharmacology"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8203-4121","authenticated-orcid":false,"given":"Michael","family":"Bartkoski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0109-0912","authenticated-orcid":false,"given":"John","family":"Tumberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9800-9278","authenticated-orcid":false,"given":"Laura","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1489-4119","authenticated-orcid":false,"given":"In-Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2087-8887","authenticated-orcid":false,"given":"Phil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2641","authenticated-orcid":false,"given":"Jeffrey R.","family":"Strawn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6227-7636","authenticated-orcid":false,"given":"William M.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-3132","authenticated-orcid":false,"given":"Stephani L.","family":"Stancil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"issue":"47","key":"683_CR1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e402","volume":"35","author":"Y Song","year":"2020","unstructured":"Song Y, et al. Comparison of suicide risk by mental illness: a retrospective review of 14-year electronic medical records. J Korean Med Sci. 2020;35(47): e402.","journal-title":"J Korean Med Sci"},{"key":"683_CR2","doi-asserted-by":"publisher","first-page":"1134032","DOI":"10.3389\/fpubh.2023.1134032","volume":"11","author":"S Defar","year":"2023","unstructured":"Defar S, et al. Health related quality of life among people with mental illness: The role of socio-clinical characteristics and level of functional disability. Front Public Health. 2023;11:1134032.","journal-title":"Front Public Health"},{"issue":"6","key":"683_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/00004583-199806000-00009","volume":"37","author":"AM Bardone","year":"1998","unstructured":"Bardone AM, et al. Adult physical health outcomes of adolescent girls with conduct disorder, depression, and anxiety. J Am Acad Child Adolesc Psychiatry. 1998;37(6):594\u2013601.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"683_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/135910539700200402","volume":"2","author":"PL Dobkin","year":"1997","unstructured":"Dobkin PL, Tremblay RE, McDuff P. Can childhood behavioural characteristics predict adolescent boys\u2019 health? A nine-year longitudinal study. J Health Psychol. 1997;2(4):445\u201356.","journal-title":"J Health Psychol"},{"issue":"4","key":"683_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/cts.13216","volume":"15","author":"SL Stancil","year":"2022","unstructured":"Stancil SL, Tumberger J, Strawn JR. Target to treatment: a charge to develop biomarkers of response and tolerability in child and adolescent psychiatry. Clin Transl Sci. 2022;15(4):816\u201323.","journal-title":"Clin Transl Sci"},{"key":"683_CR6","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2024.0099","author":"JN Stimpfl","year":"2024","unstructured":"Stimpfl JN, et al. Deprescribing antidepressants in children and adolescents: a systematic review of discontinuation approaches, cross-titration, and withdrawal symptoms. J Child Adolesc Psychopharmacol. 2024. https:\/\/doi.org\/10.1089\/cap.2024.0099.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"683_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12991-023-00480-z","volume":"22","author":"LM Garcia-Marin","year":"2023","unstructured":"Garcia-Marin LM, et al. Discontinuation of antidepressant treatment: a retrospective cohort study on more than 20,000 participants. Ann Gen Psychiatry. 2023;22(1):49.","journal-title":"Ann Gen Psychiatry"},{"issue":"9","key":"683_CR8","first-page":"26","volume":"18","author":"JB Dwyer","year":"2019","unstructured":"Dwyer JB, Bloch MH. Antidepressants for pediatric patients. Curr Psychiatr. 2019;18(9):26\u201342f.","journal-title":"Curr Psychiatr"},{"issue":"12","key":"683_CR9","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/jcpp.13250","volume":"61","author":"R Chahal","year":"2020","unstructured":"Chahal R, Gotlib IH, Guyer AE. Research review: brain network connectivity and the heterogeneity of depression in adolescence\u2014a precision mental health perspective. J Child Psychol Psychiatry. 2020;61(12):1282\u201398.","journal-title":"J Child Psychol Psychiatry"},{"issue":"10","key":"683_CR10","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1377\/hlthaff.2020.00198","volume":"39","author":"M Carmack","year":"2020","unstructured":"Carmack M, Hwang T, Bourgeois FT. Pediatric drug policies supporting safe and effective use of therapeutics in children: a systematic analysis. Health Aff (Millwood). 2020;39(10):1799\u2013805.","journal-title":"Health Aff (Millwood)"},{"issue":"10","key":"683_CR11","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.4088\/JCP.13m08797","volume":"75","author":"BR Rutherford","year":"2014","unstructured":"Rutherford BR, et al. The role of patient expectancy in placebo and nocebo effects in antidepressant trials. J Clin Psychiatry. 2014;75(10):1040\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"683_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrd3923","volume":"12","author":"P Enck","year":"2013","unstructured":"Enck P, et al. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov. 2013;12(3):191\u2013204.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"683_CR13","first-page":"233","volume":"34","author":"MC Grabb","year":"2020","unstructured":"Grabb MC, Hillefors M, Potter WZ. The NIMH \u201cFast-Fail Trials\u201d (FAST) initiative: rationale, promise, and progress. Pharmaceut Med. 2020;34(4):233\u201345.","journal-title":"Pharmaceut Med"},{"issue":"5","key":"683_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1515\/revneuro-2014-0031","volume":"25","author":"B Medhi","year":"2014","unstructured":"Medhi B, et al. Role of neuroimaging in drug development. Rev Neurosci. 2014;25(5):663\u201373.","journal-title":"Rev Neurosci"},{"issue":"2","key":"683_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/npr2.12084","volume":"40","author":"R Arakawa","year":"2020","unstructured":"Arakawa R, Takano A, Halldin C. PET technology for drug development in psychiatry. Neuropsychopharmacol Rep. 2020;40(2):114\u201321.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"6","key":"683_CR16","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/jmri.20584","volume":"23","author":"RG Wise","year":"2006","unstructured":"Wise RG, Tracey I. The role of fMRI in drug discovery. J Magn Reson Imaging. 2006;23(6):862\u201376.","journal-title":"J Magn Reson Imaging"},{"issue":"Suppl 10","key":"683_CR17","first-page":"3","volume":"58","author":"CA Tamminga","year":"1997","unstructured":"Tamminga CA, Conley RR. The application of neuroimaging techniques to drug development. J Clin Psychiatry. 1997;58(Suppl 10):3\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"683_CR18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.chc.2012.07.010","volume":"21","author":"MK Singh","year":"2012","unstructured":"Singh MK, Chang KD. The neural effects of psychotropic medications in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2012;21(4):753\u201371.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"1","key":"683_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2463\/mrms.rev.2021-0011","volume":"21","author":"H Kabasawa","year":"2022","unstructured":"Kabasawa H. MR imaging in the 21st century: technical innovation over the first two decades. Magn Reson Med Sci. 2022;21(1):71\u201382.","journal-title":"Magn Reson Med Sci"},{"issue":"3","key":"683_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11065-015-9294-9","volume":"25","author":"JE Chen","year":"2015","unstructured":"Chen JE, Glover GH. Functional magnetic resonance imaging methods. Neuropsychol Rev. 2015;25(3):289\u2013313.","journal-title":"Neuropsychol Rev"},{"issue":"3","key":"683_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jceh.2015.08.001","volume":"5","author":"VP Grover","year":"2015","unstructured":"Grover VP, et al. Magnetic resonance imaging: principles and techniques: lessons for clinicians. J Clin Exp Hepatol. 2015;5(3):246\u201355.","journal-title":"J Clin Exp Hepatol"},{"key":"683_CR22","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.12f01472","author":"JR Stevens","year":"2013","unstructured":"Stevens JR, Wilens TE, Stern TA. Using stimulants for attention-deficit\/hyperactivity disorder: clinical approaches and challenges. Prim Care Companion CNS Disord. 2013. https:\/\/doi.org\/10.4088\/PCC.12f01472.","journal-title":"Prim Care Companion CNS Disord"},{"key":"683_CR23","unstructured":"Fedder D, Patel H, Saadabadi A. Atomoxetine. In: StatPearls. 2024, StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC: Treasure Island."},{"issue":"15","key":"683_CR24","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1517\/14656566.2012.721778","volume":"13","author":"OG Bukstein","year":"2012","unstructured":"Bukstein OG, Head J. Guanfacine ER for the treatment of adolescent attention-deficit\/hyperactivity disorder. Expert Opin Pharmacother. 2012;13(15):2207\u201313.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"683_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1503\/jpn.130290","volume":"40","author":"SB Hong","year":"2015","unstructured":"Hong SB, et al. Functional dysconnectivity of corticostriatal circuitry and differential response to methylphenidate in youth with attention-deficit\/hyperactivity disorder. J Psychiatry Neurosci. 2015;40(1):46\u201357.","journal-title":"J Psychiatry Neurosci"},{"issue":"10","key":"683_CR26","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00213-023-06422-7","volume":"240","author":"OS Kowalczyk","year":"2023","unstructured":"Kowalczyk OS, et al. Single-dose effects of methylphenidate and atomoxetine on functional connectivity during an n-back task in boys with ADHD. Psychopharmacology. 2023;240(10):2045\u201360.","journal-title":"Psychopharmacology"},{"issue":"5","key":"683_CR27","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1007\/s11682-016-9620-8","volume":"11","author":"TJ Silk","year":"2017","unstructured":"Silk TJ, et al. The effect of single-dose methylphenidate on resting-state network functional connectivity in ADHD. Brain Imaging Behav. 2017;11(5):1422\u201331.","journal-title":"Brain Imaging Behav"},{"issue":"7","key":"683_CR28","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/npp.2013.27","volume":"38","author":"L An","year":"2013","unstructured":"An L, et al. Methylphenidate normalizes resting-state brain dysfunction in boys with attention deficit hyperactivity disorder. Neuropsychopharmacology. 2013;38(7):1287\u201395.","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"683_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1089\/cap.2015.0221","volume":"26","author":"L Battel","year":"2016","unstructured":"Battel L, et al. Intrinsic brain connectivity following long-term treatment with methylphenidate in children with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016;26(6):555\u201361.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"9","key":"683_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/ijnp\/pyac028","volume":"25","author":"Z Fu","year":"2022","unstructured":"Fu Z, et al. Shared and unique effects of long-term administration of methylphenidate and atomoxetine on degree centrality in medication-naive children with attention-deficit\/hyperactive disorder. Int J Neuropsychopharmacol. 2022;25(9):709\u201319.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"7","key":"683_CR31","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jaac.2017.04.005","volume":"56","author":"KP Schulz","year":"2017","unstructured":"Schulz KP, et al. Striatal activation predicts differential therapeutic responses to methylphenidate and atomoxetine. J Am Acad Child Adolesc Psychiatry. 2017;56(7):602\u20139 (e2).","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"683_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1177\/0269881117715607","volume":"31","author":"Z-M Wu","year":"2017","unstructured":"Wu Z-M, et al. Verbal working memory-related functional connectivity alterations in boys with attention-deficit\/hyperactivity disorder and the effects of methylphenidate. J Psychopharmacol. 2017;31(8):1061\u20139.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"683_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/jcpp.13480","volume":"63","author":"SP Hinshaw","year":"2022","unstructured":"Hinshaw SP, et al. Annual research review: attention-deficit\/hyperactivity disorder in girls and women: underrepresentation, longitudinal processes, and key directions. J Child Psychol Psychiatry. 2022;63(4):484\u201396.","journal-title":"J Child Psychol Psychiatry"},{"issue":"10","key":"683_CR34","volume":"14","author":"RM Pettitt","year":"2022","unstructured":"Pettitt RM, et al. The management of anxiety and depression in pediatrics. Cureus. 2022;14(10): e30231.","journal-title":"Cureus"},{"issue":"5","key":"683_CR35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopsych.2005.08.012","volume":"59","author":"KL Phan","year":"2006","unstructured":"Phan KL, et al. Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol Psychiatry. 2006;59(5):424\u20139.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"683_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2174\/1570159X15666171123201142","volume":"16","author":"JC Felger","year":"2018","unstructured":"Felger JC. Imaging the role of inflammation in mood and anxiety-related disorders. Curr Neuropharmacol. 2018;16(5):533\u201358.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"683_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0091-3057(01)00687-6","volume":"71","author":"WC Drevets","year":"2002","unstructured":"Drevets WC, et al. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav. 2002;71(3):431\u201347.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"683_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41398-018-0332-2","volume":"9","author":"LP Capitao","year":"2019","unstructured":"Capitao LP, et al. A single dose of fluoxetine reduces neural limbic responses to anger in depressed adolescents. Transl Psychiatry. 2019;9(1):30.","journal-title":"Transl Psychiatry"},{"issue":"5","key":"683_CR39","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/s41386-021-01186-0","volume":"47","author":"L Lu","year":"2022","unstructured":"Lu L, et al. Acute neurofunctional effects of escitalopram during emotional processing in pediatric anxiety: a double-blind, placebo-controlled trial. Neuropsychopharmacology. 2022;47(5):1081\u20137.","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"683_CR40","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaac.2020.11.023","volume":"60","author":"L Lu","year":"2021","unstructured":"Lu L, et al. Acute neurofunctional effects of escitalopram in pediatric anxiety: a double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2021;60(10):1309\u201318.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"683_CR41","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1007\/s00213-014-3837-2","volume":"232","author":"K Chantiluke","year":"2015","unstructured":"Chantiluke K, et al. Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD. Psychopharmacology. 2015;232(12):2071\u201382.","journal-title":"Psychopharmacology"},{"issue":"7","key":"683_CR42","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1093\/cercor\/bht365","volume":"25","author":"K Chantiluke","year":"2015","unstructured":"Chantiluke K, et al. Inverse effect of fluoxetine on medial prefrontal cortex activation during reward reversal in ADHD and autism. Cereb Cortex. 2015;25(7):1757\u201370.","journal-title":"Cereb Cortex"},{"issue":"Pt A","key":"683_CR43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pnpbp.2018.03.013","volume":"84","author":"KL Burkhouse","year":"2018","unstructured":"Burkhouse KL, et al. Anterior cingulate activation to implicit threat before and after treatment for pediatric anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2018;84(Pt A):250\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"683_CR44","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/cap.2015.0232","volume":"26","author":"KR Cullen","year":"2016","unstructured":"Cullen KR, et al. Neural correlates of antidepressant treatment response in adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2016;26(8):705\u201312.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"683_CR45","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1017\/S0033291714002232","volume":"45","author":"K Chantiluke","year":"2015","unstructured":"Chantiluke K, et al. Disorder-dissociated effects of fluoxetine on brain function of working memory in attention deficit hyperactivity disorder and autism spectrum disorder. Psychol Med. 2015;45(6):1195\u2013205.","journal-title":"Psychol Med"},{"issue":"6","key":"683_CR46","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1017\/S0033291715002731","volume":"46","author":"CO Carlisi","year":"2016","unstructured":"Carlisi CO, et al. The effects of acute fluoxetine administration on temporal discounting in youth with ADHD. Psychol Med. 2016;46(6):1197\u2013209.","journal-title":"Psychol Med"},{"issue":"2","key":"683_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/cap.2009.0049","volume":"20","author":"J Maslowsky","year":"2010","unstructured":"Maslowsky J, et al. A preliminary investigation of neural correlates of treatment in adolescents with generalized anxiety disorder. J Child Adolesc Psychopharmacol. 2010;20(2):105\u201311.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"683_CR48","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/npp.2015.368","volume":"41","author":"A Kujawa","year":"2016","unstructured":"Kujawa A, et al. Prefrontal reactivity to social signals of threat as a predictor of treatment response in anxious youth. Neuropsychopharmacology. 2016;41(8):1983\u201390.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"683_CR49","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1590\/1516-4446-2019-0732","volume":"42","author":"G Scaini","year":"2020","unstructured":"Scaini G, et al. Neurobiology of bipolar disorders: a review of genetic components, signaling pathways, biochemical changes, and neuroimaging findings. Braz J Psychiatry. 2020;42(5):536\u201351.","journal-title":"Braz J Psychiatry"},{"issue":"6","key":"683_CR50","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2174\/1570159X21666230126153105","volume":"21","author":"D Janiri","year":"2023","unstructured":"Janiri D, et al. Use of lithium in pediatric bipolar disorders and externalizing childhood-related disorders: a systematic review of randomized controlled trials. Curr Neuropharmacol. 2023;21(6):1329\u201342.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"683_CR51","first-page":"6","volume":"24","author":"A Schaffer","year":"2012","unstructured":"Schaffer A, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012;24(1):6\u201322.","journal-title":"Ann Clin Psychiatry"},{"issue":"2","key":"683_CR52","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jad.2013.02.007","volume":"150","author":"H Yang","year":"2013","unstructured":"Yang H, et al. Time course of recovery showing initial prefrontal cortex changes at 16 weeks, extending to subcortical changes by 3 years in pediatric bipolar disorder. J Affect Disord. 2013;150(2):571\u20137.","journal-title":"J Affect Disord"},{"issue":"6","key":"683_CR53","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/cap.2017.0030","volume":"28","author":"K Chang","year":"2018","unstructured":"Chang K, et al. Neurofunctional correlates of response to quetiapine in adolescents with bipolar depression. J Child Adolesc Psychopharmacol. 2018;28(6):379\u201386.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"683_CR54","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41386-022-01463-6","volume":"48","author":"D Lei","year":"2023","unstructured":"Lei D, et al. Effects of short-term quetiapine and lithium therapy for acute manic or mixed episodes on the limbic system and emotion regulation circuitry in youth with bipolar disorder. Neuropsychopharmacology. 2023;48(4):615\u201322.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"683_CR55","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41386-021-00989-5","volume":"46","author":"D Lei","year":"2021","unstructured":"Lei D, et al. Changes in the brain structural connectome after a prospective randomized clinical trial of lithium and quetiapine treatment in youth with bipolar disorder. Neuropsychopharmacology. 2021;46(7):1315\u201323.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"683_CR56","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jaac.2021.12.015","volume":"61","author":"W Li","year":"2022","unstructured":"Li W, et al. Pretreatment alterations and acute medication treatment effects on brain task-related functional connectivity in youth with bipolar disorder: a neuroimaging randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2022;61(8):1023\u201333.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"683_CR57","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1177\/0269881120928203","volume":"35","author":"AV Roy","year":"2021","unstructured":"Roy AV, et al. Brain entropy and neurotrophic molecular markers accompanying clinical improvement after ketamine: preliminary evidence in adolescents with treatment-resistant depression. J Psychopharmacol. 2021;35(2):168\u201377.","journal-title":"J Psychopharmacol"},{"key":"683_CR58","doi-asserted-by":"publisher","first-page":"1161032","DOI":"10.3389\/fpsyt.2023.1161032","volume":"14","author":"SL Stancil","year":"2023","unstructured":"Stancil SL, et al. Potential biomarker of brain response to opioid antagonism in adolescents with eating disorders: a pilot study. Front Psychiatry. 2023;14:1161032.","journal-title":"Front Psychiatry"},{"issue":"3","key":"683_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.29","volume":"6","author":"RJ Mocking","year":"2016","unstructured":"Mocking RJ, et al. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry. 2016;6(3): e756.","journal-title":"Transl Psychiatry"},{"key":"683_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plipres.2017.01.001","volume":"66","author":"E Messamore","year":"2017","unstructured":"Messamore E, et al. Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application. Prog Lipid Res. 2017;66:1\u201313.","journal-title":"Prog Lipid Res"},{"issue":"2","key":"683_CR61","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/bdi.13110","volume":"24","author":"RK McNamara","year":"2022","unstructured":"McNamara RK, et al. Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial. Bipolar Disord. 2022;24(2):161\u201370.","journal-title":"Bipolar Disord"},{"issue":"12","key":"683_CR62","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jaac.2018.06.026","volume":"57","author":"K van Lith","year":"2018","unstructured":"van Lith K, et al. Effects of methylphenidate during fear learning in antisocial adolescents: a randomized controlled fMRI trial. J Am Acad Child Adolesc Psychiatry. 2018;57(12):934\u201343.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"683_CR63","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s11682-017-9713-z","volume":"12","author":"JH Yoo","year":"2018","unstructured":"Yoo JH, et al. Treatment effect of methylphenidate on intrinsic functional brain network in medication-naive ADHD children: a multivariate analysis. Brain Imaging Behav. 2018;12(2):518\u201331.","journal-title":"Brain Imaging Behav"},{"issue":"14","key":"683_CR64","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1177\/1087054713517542","volume":"21","author":"L Querne","year":"2017","unstructured":"Querne L, et al. Effects of methylphenidate on default-mode network\/task-positive network synchronization in children with ADHD. J Atten Disord. 2017;21(14):1208\u201320.","journal-title":"J Atten Disord"},{"issue":"1","key":"683_CR65","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/hbm.22634","volume":"36","author":"SB Hong","year":"2015","unstructured":"Hong SB, et al. COMT genotype affects brain white matter pathways in attention-deficit\/hyperactivity disorder. Hum Brain Mapp. 2015;36(1):367\u201377.","journal-title":"Hum Brain Mapp"},{"issue":"10","key":"683_CR66","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.euroneuro.2019.07.139","volume":"29","author":"OS Kowalczyk","year":"2019","unstructured":"Kowalczyk OS, et al. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents. Eur Neuropsychopharmacol. 2019;29(10):1102\u201316.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"15","key":"683_CR67","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1017\/S0033291716001938","volume":"46","author":"CY Shang","year":"2016","unstructured":"Shang CY, et al. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder. Psychol Med. 2016;46(15):3173\u201385.","journal-title":"Psychol Med"},{"issue":"1","key":"683_CR68","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/cercor\/bhs296","volume":"24","author":"A Cubillo","year":"2014","unstructured":"Cubillo A, et al. Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys. Cereb Cortex. 2014;24(1):174\u201385.","journal-title":"Cereb Cortex"},{"issue":"3","key":"683_CR69","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1017\/S0033291713000676","volume":"44","author":"A Cubillo","year":"2014","unstructured":"Cubillo A, et al. Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory. Psychol Med. 2014;44(3):633\u201346.","journal-title":"Psychol Med"},{"issue":"8","key":"683_CR70","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.biopsych.2013.03.030","volume":"74","author":"A Smith","year":"2013","unstructured":"Smith A, et al. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit\/hyperactivity disorder during time discrimination. Biol Psychiatry. 2013;74(8):615\u201322.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"683_CR71","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1001\/archgenpsychiatry.2011.2053","volume":"69","author":"KP Schulz","year":"2012","unstructured":"Schulz KP, et al. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit\/hyperactivity disorder. Arch Gen Psychiatry. 2012;69(9):952\u201361.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"683_CR72","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.pscychresns.2015.01.012","volume":"231","author":"AC Bedard","year":"2015","unstructured":"Bedard AC, et al. Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: a pilot fMRI study. Psychiatry Res. 2015;231(3):353\u20136.","journal-title":"Psychiatry Res"},{"issue":"7","key":"683_CR73","doi-asserted-by":"publisher","first-page":"e790","DOI":"10.4088\/JCP.15m10624","volume":"78","author":"LJS Schweren","year":"2017","unstructured":"Schweren LJS, et al. Stimulant treatment trajectories are associated with neural reward processing in attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2017;78(7):e790\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"683_CR74","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jaac.2015.05.014","volume":"54","author":"LJ Schweren","year":"2015","unstructured":"Schweren LJ, et al. Thinner medial temporal cortex in adolescents with attention-deficit\/hyperactivity disorder and the effects of stimulants. J Am Acad Child Adolesc Psychiatry. 2015;54(8):660\u20137.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"683_CR75","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1087054712443158","volume":"18","author":"M Semrud-Clikeman","year":"2014","unstructured":"Semrud-Clikeman M, et al. Volumetric MRI differences in treatment naive and chronically treated adolescents with ADHD-combined type. J Atten Disord. 2014;18(6):511\u201320.","journal-title":"J Atten Disord"},{"issue":"12","key":"683_CR76","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1177\/0269881120959608","volume":"34","author":"LP Capitao","year":"2020","unstructured":"Capitao LP, et al. Neural effects of a single dose of fluoxetine on resting-state functional connectivity in adolescent depression. J Psychopharmacol. 2020;34(12):1461\u20135.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"683_CR77","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaac.2018.07.897","volume":"58","author":"GA Bernstein","year":"2019","unstructured":"Bernstein GA, et al. Sertraline effects on striatal resting-state functional connectivity in youth with obsessive-compulsive disorder: a pilot study. J Am Acad Child Adolesc Psychiatry. 2019;58(5):486\u201395.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"683_CR78","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/jcpp.12658","volume":"58","author":"KL Burkhouse","year":"2017","unstructured":"Burkhouse KL, et al. Neural correlates of explicit and implicit emotion processing in relation to treatment response in pediatric anxiety. J Child Psychol Psychiatry. 2017;58(5):546\u201354.","journal-title":"J Child Psychol Psychiatry"},{"issue":"9","key":"683_CR79","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1017\/S0033291722000757","volume":"53","author":"D Lei","year":"2023","unstructured":"Lei D, et al. Brain morphometric features predict medication response in youth with bipolar disorder: a prospective randomized clinical trial. Psychol Med. 2023;53(9):4083\u201393.","journal-title":"Psychol Med"},{"issue":"3","key":"683_CR80","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pscychresns.2014.04.011","volume":"223","author":"MR Schneider","year":"2014","unstructured":"Schneider MR, et al. The effects of carbamazepine on prefrontal activation in manic youth with bipolar disorder. Psychiatry Res. 2014;223(3):268\u201370.","journal-title":"Psychiatry Res"},{"issue":"2","key":"683_CR81","first-page":"112","volume":"49","author":"MR Schneider","year":"2012","unstructured":"Schneider MR, et al. The effects of ziprasidone on prefrontal and amygdalar activation in manic youth with bipolar disorder. Isr J Psychiatry Relat Sci. 2012;49(2):112\u201320.","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"683_CR82","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jpsychires.2014.07.023","volume":"58","author":"DM Hafeman","year":"2014","unstructured":"Hafeman DM, et al. Abnormal deactivation of the inferior frontal gyrus during implicit emotion processing in youth with bipolar disorder: attenuated by medication. J Psychiatr Res. 2014;58:129\u201336.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"683_CR83","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11682-012-9219-7","volume":"7","author":"RS Diler","year":"2013","unstructured":"Diler RS, et al. Neural correlates of treatment response in depressed bipolar adolescents during emotion processing. Brain Imaging Behav. 2013;7(2):227\u201335.","journal-title":"Brain Imaging Behav"},{"issue":"3","key":"683_CR84","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1089\/cap.2012.0054","volume":"23","author":"RS Diler","year":"2013","unstructured":"Diler RS, et al. Neural correlates of treatment in adolescents with bipolar depression during response inhibition. J Child Adolesc Psychopharmacol. 2013;23(3):214\u201321.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"683_CR85","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00213-019-05344-7","volume":"238","author":"A Egerton","year":"2021","unstructured":"Egerton A. The potential of (1)H-MRS in CNS drug development. Psychopharmacology. 2021;238(5):1241\u201354.","journal-title":"Psychopharmacology"},{"issue":"1","key":"683_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11064-013-1199-5","volume":"39","author":"CD Rae","year":"2014","unstructured":"Rae CD. A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res. 2014;39(1):1\u201336.","journal-title":"Neurochem Res"},{"issue":"3","key":"683_CR87","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.rcl.2021.01.004","volume":"59","author":"BD Weinberg","year":"2021","unstructured":"Weinberg BD, et al. Clinical applications of magnetic resonance spectroscopy in brain tumors: from diagnosis to treatment. Radiol Clin N Am. 2021;59(3):349\u201362.","journal-title":"Radiol Clin N Am"},{"issue":"7","key":"683_CR88","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1517\/17460441.2013.795144","volume":"8","author":"BD Ross","year":"2013","unstructured":"Ross BD. High-field MRS in clinical drug development. Expert Opin Drug Discov. 2013;8(7):849\u201363.","journal-title":"Expert Opin Drug Discov"},{"issue":"1\u20132","key":"683_CR89","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.pscychresns.2014.03.003","volume":"222","author":"V Husarova","year":"2014","unstructured":"Husarova V, et al. Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit\/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study. Psychiatry Res. 2014;222(1\u20132):75\u201383.","journal-title":"Psychiatry Res"},{"issue":"4","key":"683_CR90","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/metabo13040577","volume":"13","author":"P Veeraiah","year":"2023","unstructured":"Veeraiah P, Jansen JFA. Multinuclear magnetic resonance spectroscopy at ultra-high-field: assessing human cerebral metabolism in healthy and diseased states. Metabolites. 2023;13(4):577.","journal-title":"Metabolites"},{"issue":"5","key":"683_CR91","doi-asserted-by":"crossref","first-page":"I-S43","DOI":"10.1016\/j.jpeds.2009.01.018","volume":"154","author":"AF Arnsten","year":"2009","unstructured":"Arnsten AF. The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr. 2009;154(5):I-S43.","journal-title":"J Pediatr"},{"issue":"9","key":"683_CR92","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.acra.2007.05.017","volume":"14","author":"N Fayed","year":"2007","unstructured":"Fayed N, et al. Evidence of brain dysfunction in attention deficit-hyperactivity disorder: a controlled study with proton magnetic resonance spectroscopy. Acad Radiol. 2007;14(9):1029\u201335.","journal-title":"Acad Radiol"},{"issue":"1","key":"683_CR93","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pscychresns.2011.01.017","volume":"201","author":"L L\u00e1zaro","year":"2012","unstructured":"L\u00e1zaro L, et al. Proton magnetic resonance spectroscopy in pediatric obsessive-compulsive disorder: longitudinal study before and after treatment. Psychiatry Res. 2012;201(1):17\u201324.","journal-title":"Psychiatry Res"},{"issue":"4","key":"683_CR94","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1089\/cap.2011.0153","volume":"22","author":"K Chang","year":"2012","unstructured":"Chang K, et al. Neurometabolite effects of response to quetiapine and placebo in adolescents with bipolar depression. J Child Adolesc Psychopharmacol. 2012;22(4):261\u20138.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"683_CR95","unstructured":"Constance MM, Janet Wozniak JB, Eric M, Megan A, Megan W, Meghan D, Terri H, Paul H, Edin R, In KL, Perry FR. Mania, glutamate:glutamine and risperidone in pediatric bipolar disorder\u2014a proton magnetic resonance spectroscopy study of the anterior cingulate cortex. 2006."},{"issue":"8","key":"683_CR96","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s00726-016-2194-3","volume":"48","author":"DG Kondo","year":"2016","unstructured":"Kondo DG, et al. Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression. Amino Acids. 2016;48(8):1941\u201354.","journal-title":"Amino Acids"},{"issue":"5","key":"683_CR97","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/cap.2019.0124","volume":"30","author":"RK McNamara","year":"2020","unstructured":"McNamara RK, et al. Effects of fish oil monotherapy on depression and prefrontal neurochemistry in adolescents at high risk for bipolar I disorder: a 12-week placebo-controlled proton magnetic resonance spectroscopy trial. J Child Adolesc Psychopharmacol. 2020;30(5):293\u2013305.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"683_CR98","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jaac.2012.03.009","volume":"51","author":"JR Strawn","year":"2012","unstructured":"Strawn JR, et al. Glutamatergic effects of divalproex in manic adolescents: a proton magnetic resonance spectroscopy study. J Am Acad Child Adolesc Psychiatry. 2012;51(6):642\u201351.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"683_CR99","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pscychresns.2014.04.010","volume":"223","author":"JL Gan","year":"2014","unstructured":"Gan JL, et al. Atypical antipsychotic drug treatment for 6 months restores N-acetylaspartate in left prefrontal cortex and left thalamus of first-episode patients with early onset schizophrenia: a magnetic resonance spectroscopy study. Psychiatry Res. 2014;223(1):23\u20137.","journal-title":"Psychiatry Res"},{"issue":"4","key":"683_CR100","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1179\/1476830514Y.0000000135","volume":"19","author":"RK McNamara","year":"2016","unstructured":"McNamara RK, et al. Effects of fish oil supplementation on prefrontal metabolite concentrations in adolescents with major depressive disorder: a preliminary 1H MRS study. Nutr Neurosci. 2016;19(4):145\u201355.","journal-title":"Nutr Neurosci"},{"key":"683_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.812270","volume":"9","author":"SG Nerella","year":"2022","unstructured":"Nerella SG, et al. PET Molecular imaging in drug development: the imaging and chemistry perspective. Front Med (Lausanne). 2022;9: 812270.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"683_CR102","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2967\/jnumed.116.188045","volume":"59","author":"SJH Waaijer","year":"2018","unstructured":"Waaijer SJH, et al. Molecular imaging in cancer drug development. J Nucl Med. 2018;59(5):726\u201332.","journal-title":"J Nucl Med"},{"issue":"4","key":"683_CR103","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cpet.2009.04.006","volume":"3","author":"A Kumar","year":"2008","unstructured":"Kumar A, Chugani HT. PET in the assessment of pediatric brain development and developmental disorders. PET Clin. 2008;3(4):487\u2013515.","journal-title":"PET Clin"},{"issue":"5","key":"683_CR104","doi-asserted-by":"publisher","first-page":"W510","DOI":"10.2214\/AJR.14.13892","volume":"204","author":"SL Brady","year":"2015","unstructured":"Brady SL, Mohaupt TH, Kaufman RA. A comprehensive risk assessment method for pediatric patients undergoing research examinations using ionizing radiation: how we answered the Institutional Review Board. AJR Am J Roentgenol. 2015;204(5):W510\u20138.","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"683_CR105","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1472-8206.2008.00650.x","volume":"22","author":"L Zimmer","year":"2008","unstructured":"Zimmer L. Can positron emission tomography facilitate paediatric drug development? Fundam Clin Pharmacol. 2008;22(6):595\u20138.","journal-title":"Fundam Clin Pharmacol"},{"issue":"5 Suppl","key":"683_CR106","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.jadohealth.2013.03.006","volume":"52","author":"KE Applegate","year":"2013","unstructured":"Applegate KE, Cost NG. Image gently: a campaign to reduce children\u2019s and adolescents\u2019 risk for cancer during adulthood. J Adolesc Health. 2013;52(5 Suppl):S93\u20137.","journal-title":"J Adolesc Health"},{"issue":"9","key":"683_CR107","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.2967\/jnumed.116.189290","volume":"58","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, et al. Alteration of monoamine receptor activity and glucose metabolism in pediatric patients with anticonvulsant-induced cognitive impairment. J Nucl Med. 2017;58(9):1490\u20137.","journal-title":"J Nucl Med"},{"issue":"5","key":"683_CR108","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","volume":"161","author":"JH Meyer","year":"2004","unstructured":"Meyer JH, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161(5):826\u201335.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"683_CR109","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, et al. Lecanemab: appropriate use recommendations. JPAD J Prev Alzheimers Dis. 2023;10(3):362\u201377.","journal-title":"JPAD J Prev Alzheimers Dis"},{"issue":"1","key":"683_CR110","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"key":"683_CR111","unstructured":"Group F-NBW. In: BEST (Biomarkers, EndpointS, and other Tools) Resource. 2016, Food and Drug Administration (US) National Institutes of Health (US). Bethesda: Silver Spring."},{"issue":"4","key":"683_CR112","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1001\/jamapsychiatry.2023.5483","volume":"81","author":"A Sangchooli","year":"2024","unstructured":"Sangchooli A, et al. Parameter space and potential for biomarker development in 25 years of fMRI drug cue reactivity: a systematic review. JAMA Psychiat. 2024;81(4):414\u201325.","journal-title":"JAMA Psychiat"},{"issue":"7","key":"683_CR113","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/hbm.22386","volume":"35","author":"H Hart","year":"2014","unstructured":"Hart H, et al. Pattern classification of response inhibition in ADHD: toward the development of neurobiological markers for ADHD. Hum Brain Mapp. 2014;35(7):3083\u201394.","journal-title":"Hum Brain Mapp"},{"key":"683_CR114","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41386-024-01917-z","volume":"50","author":"LM Williams","year":"2024","unstructured":"Williams LM, Gabrieli SW. Neuroimaging for precision medicine in psychiatry. Neuropsychopharmacology. 2024;50:246\u201357.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"683_CR115","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/humu.22080","volume":"33","author":"PN Robinson","year":"2012","unstructured":"Robinson PN. Deep phenotyping for precision medicine. Hum Mutat. 2012;33(5):777\u201380.","journal-title":"Hum Mutat"},{"key":"683_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118579","volume":"244","author":"AR Laird","year":"2021","unstructured":"Laird AR. Large, open datasets for human connectomics research: Considerations for reproducible and responsible data use. Neuroimage. 2021;244: 118579.","journal-title":"Neuroimage"},{"key":"683_CR117","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.dcn.2018.03.001","volume":"32","author":"BJ Casey","year":"2018","unstructured":"Casey BJ, et al. The adolescent brain cognitive development (ABCD) study: imaging acquisition across 21 sites. Dev Cogn Neurosci. 2018;32:43\u201354.","journal-title":"Dev Cogn Neurosci"},{"key":"683_CR118","unstructured":"Brain Canada Foundation. The Canadian Pediatric Imaging Platform (C-PIP): a platform to support research in child brain health. 2023. https:\/\/braincanada.ca\/funded_grants\/the-canadian-pediatric-imaging-platform-c-pip-a-platform-to-support-research-in-child-brain-health\/. Accessed 28 Dec 2024."},{"issue":"4","key":"683_CR119","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/jamapsychiatry.2019.4208","volume":"77","author":"S Whitfield-Gabrieli","year":"2020","unstructured":"Whitfield-Gabrieli S, et al. Association of intrinsic brain architecture with changes in attentional and mood symptoms during development. JAMA Psychiat. 2020;77(4):378\u201386.","journal-title":"JAMA Psychiat"},{"issue":"1","key":"683_CR120","first-page":"6","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. FDA approves anti-CD3 antibody to delay type 1 diabetes onset. Nat Rev Drug Discov. 2023;22(1):6\u20137.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"683_CR121","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11682-013-9269-5","volume":"8","author":"PM Thompson","year":"2014","unstructured":"Thompson PM, et al. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav. 2014;8(2):153\u201382.","journal-title":"Brain Imaging Behav"},{"key":"683_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117164","volume":"221","author":"D Szucs","year":"2020","unstructured":"Szucs D, Ioannidis JP. Sample size evolution in neuroimaging research: An evaluation of highly-cited studies (1990\u20132012) and of latest practices (2017\u20132018) in high-impact journals. Neuroimage. 2020;221: 117164.","journal-title":"Neuroimage"},{"key":"683_CR123","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s42003-018-0073-z","volume":"1","author":"BO Turner","year":"2018","unstructured":"Turner BO, et al. Small sample sizes reduce the replicability of task-based fMRI studies. Commun Biol. 2018;1:62.","journal-title":"Commun Biol"},{"key":"683_CR124","doi-asserted-by":"crossref","unstructured":"Addiction Cue-Reactivity Initiative N, et al. Parameter space and potential for biomarker development in 25 years of fMRI drug cue reactivity: a systematic review. JAMA Psychiatry 2024; 81(4): 414\u201325.","DOI":"10.1001\/jamapsychiatry.2023.5483"},{"key":"683_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.dcn.2024.101408","volume":"68","author":"DA Lopez","year":"2024","unstructured":"Lopez DA, et al. Transparency and reproducibility in the adolescent brain cognitive development (ABCD) study. Dev Cogn Neurosci. 2024;68: 101408.","journal-title":"Dev Cogn Neurosci"},{"key":"683_CR126","doi-asserted-by":"publisher","first-page":"1045678","DOI":"10.3389\/fneur.2022.1045678","volume":"13","author":"AD Harris","year":"2022","unstructured":"Harris AD, et al. Harmonization of multi-scanner in vivo magnetic resonance spectroscopy: ENIGMA consortium task group considerations. Front Neurol. 2022;13:1045678.","journal-title":"Front Neurol"},{"key":"683_CR127","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41386-024-01973-5","volume":"50","author":"H Ekhtiari","year":"2024","unstructured":"Ekhtiari H, et al. Reporting checklists in neuroimaging: promoting transparency, replicability, and reproducibility. Neuropsychopharmacology. 2024;50:67\u201384.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"683_CR128","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.4484","volume":"34","author":"A Lin","year":"2021","unstructured":"Lin A, et al. Minimum reporting standards for in vivo magnetic resonance spectroscopy (MRSinMRS): experts\u2019 consensus recommendations. NMR Biomed. 2021;34(5): e4484.","journal-title":"NMR Biomed"},{"issue":"2","key":"683_CR129","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.neuroimage.2007.11.048","volume":"40","author":"RA Poldrack","year":"2008","unstructured":"Poldrack RA, et al. Guidelines for reporting an fMRI study. Neuroimage. 2008;40(2):409\u201314.","journal-title":"Neuroimage"},{"issue":"1","key":"683_CR130","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41597-024-02959-0","volume":"11","author":"D Levitas","year":"2024","unstructured":"Levitas D, et al. ezBIDS: guided standardization of neuroimaging data interoperable with major data archives and platforms. Sci Data. 2024;11(1):179.","journal-title":"Sci Data"},{"key":"683_CR131","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71774","author":"CJ Markiewicz","year":"2021","unstructured":"Markiewicz CJ, et al. The OpenNeuro resource for sharing of neuroscience data. Elife. 2021. https:\/\/doi.org\/10.7554\/eLife.71774.","journal-title":"Elife"},{"issue":"1","key":"683_CR132","first-page":"70","volume":"9","author":"HC Becker","year":"2024","unstructured":"Becker HC, et al. Changes in brain network connections after exposure and response prevention therapy for obsessive-compulsive disorder in adolescents and adults. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9(1):70\u20139.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"7","key":"683_CR133","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/brainsci12070934","volume":"12","author":"H Baldwin","year":"2022","unstructured":"Baldwin H, et al. Real-world implementation of precision psychiatry: a systematic review of barriers and facilitators. Brain Sci. 2022;12(7):934.","journal-title":"Brain Sci"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00683-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00683-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T12:04:13Z","timestamp":1745582653000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00683-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":133,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00683-9","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"14 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by grants from the National Institutes of Health (SLS\u2014K23MH130728, KL2TR002367, P30HD106451). The contents are solely the authors\u2019 responsibility and do not necessarily represent the official views of the NIH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Strawn has received research support from Abbvie, PCORI, MindMed, and the National Institutes of Health. He has provided consultation to Abbvie, Alkermes, Cerevel (now AbbVie), Intracellular Therapeutics, Genomind, and Otsuka. He receives royalties from Springer Publishing, Cambridge University Press, and UpToDate, as well as material support from Myriad. He has also received honoraria from Medscape Live, the Neuroscience Education Institute. The other authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data used in the preparation of this manuscript are available from the cited sources referenced in the paper.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"J.T., M.B., and S.L.S. conceptualized the content, drafted the initial manuscript, and critically reviewed and revised subsequent versions. L.M., I.C., P.L., W.M.B., and J.R.S. provided technical expertise, contributed to revisions, and critically reviewed the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}